January 2026 in “British Journal of Clinical Pharmacology” In this study, reports from individuals using Serenoa repens indicated a possible post-Serenoa syndrome characterized by persistent sexual and neuropsychiatric symptoms, with causality assessed as 'probable' in 54% of cases, highlighting an underrecognized safety concern that warrants further investigation.
14 citations
,
December 2016 in “Sexual Medicine” This study identified differences in adverse symptoms among patients with post-finasteride syndrome based on short and long androgen receptor gene polymorphisms.
March 2017 in “European Urology Supplements” This study found that variations in (CAG)n and (GGN)n polymorphisms in the androgen receptor gene appear to influence symptom severity in men with post-finasteride syndrome.
10 citations
,
May 2018 in “Neuropharmacology” This study suggests that inhibitors of steroidogenic enzymes may have therapeutic potential for certain behavioral disorders linked to dopaminergic hyperfunction, despite concerns about their endocrine impacts.
4 citations
,
July 2021 in “Journal of Dermatological Treatment” This meta-analysis reported that finasteride 1 mg/day significantly increased hair count in male androgenetic alopecia compared to placebo, but highlighted persistent sexual side effects and associated depression risk.
